HomeNKB2 • FRA
add
TG Therapeutics Inc common stock
Previous close
€29.80
Day range
€29.69 - €29.69
Year range
€12.08 - €34.17
Market cap
4.86B USD
Avg Volume
170.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
MarketBeat
1 day ago
Neo Ivy Capital Management Buys New Shares in TG Therapeutics, Inc.
(NASDAQ:TGTX)
1.42%
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 83.88M | -49.41% |
Operating expense | 62.10M | 30.68% |
Net income | 3.88M | -96.59% |
Net profit margin | 4.63 | -93.26% |
Earnings per share | 0.02 | -97.26% |
EBITDA | 12.44M | -89.16% |
Effective tax rate | 9.09% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 341.04M | 48.82% |
Total assets | 586.01M | 77.01% |
Total liabilities | 393.86M | 136.84% |
Total equity | 192.16M | — |
Shares outstanding | 143.52M | — |
Price to book | 22.24 | — |
Return on assets | 6.30% | — |
Return on capital | 8.44% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 3.88M | -96.59% |
Cash from operations | -12.20M | -114.58% |
Cash from investing | -9.33M | 69.12% |
Cash from financing | 134.45M | 31,836.82% |
Net change in cash | 112.92M | 109.51% |
Free cash flow | -31.00M | -181.67% |
About
Founded
1993
Headquarters
Website
Employees
319
